2018-02-26 - OBSERVABLE Meeting

1

Welcome & apologies

Daniel Karlsson

2

Conflicts of interest

Daniel Karlsson

• None stated
  
  

3

Previous minutes

Daniel Karlsson

4

LOINC collaboration

Farzaneh Ashrafi

Daniel Karlsson

Rob Hausam

+all

• Likelihood

  • Two distinct cases were identified:

    1. Specifying certainty (or uncertainty) about the result of an observation. Examples: Fetal sex, Trisomy 21 present by "Dosage of chromosome specific cf DNA" method.

    2. Prediction of a possible future event based on varying amount of information about the patient, from population-only based assessment (i.e. prevalence) to assessment based on several variables. Examples include 1p36 deletion risk based on population risk, Trisomy 21 risk based on maternal age, to the CHADS-VASC instrument.

Example values:

• Still waiting for input from Jim Case, Daniel Karlsson to remind

5

Susceptibility

Farzaneh Ashrafi

• Mapping of LOINC component for Susceptibility LOINC terms

  • Two alternatives for representing LOINC component / SNOMED Towards:

    1. Use substances: have to add combined substances for combined antibiotics, e.g. Amoxicillin+Clavulanic acid. Cannot represent strenghts. Cannot represent only vs. contains semantics(?).

    2. Use products: Depending on drug project, may represent only/contains, can represent strengh, can represent combinations

  • However, only/contains semanstics might be less of an issue, combined substances can be added according to guidelines, antibiotic strength LOINC terms seem to be just a way to represent MIC(??).

6

Next meeting

Daniel Karlsson

• Next meeting is on the 2018-03-05 20.00 UTC

7

Face-to-face

Daniel Karlsson

• LOINC - SNOMED issues (1h)

9

AOB

Daniel Karlsson